Main Conference - Day 1 Keynote Sessions (May 15)
Aldevron’s significantly expanded mRNA capabilities includes enhancements to drug product and drug substance manufacturing, as well as advanced analytical testing capabilities. At this luncheon, learn more about those advancements, and how Aldevron continues to expand its sequence-to-vial mRNA ecosystem.
The discovery of the incretin system and the therapeutic benefits of glucagon-like peptide 1 (GLP-1) has prompted a wave of innovation, resulting in new classes of highly effective therapies for type 2 diabetes. Leveraging these therapies for their weight regulation effects has produced a fresh wave of innovation and the advent of novel, highly effective therapies for weight management. We will review emerging gut peptide-derived therapeutics for glucose and weight management, their mechanisms of action, and some unknowns and controversies.
This panel will explore the anticipated technical and clinical advancements in mRNA medicine over the next 3-5 years that will show the utility of the field in addressing key unmet medical needs in oncology, infectious disease, cardiovascular disease, automimmune, and rare diseases. This will include discussions of saRNA, circular RNA, and the critical role mRNA and non-viral delivery are playing in various gene and base editing modalities.